Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial
To determine predictive/prognostic factors for patients with metastatic breast cancer (MBC) receiving first-line monochemotherapy using biomarker analysis and geriatric assessment (GA). Karnofsky Performance Status (KPS) and GA as clinical parameters, and prognostic inflammatory and nutritional inde...
Gespeichert in:
| Veröffentlicht in: | Journal of geriatric oncology 2018-03, Vol.9 (2), p.163-169 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 169 |
|---|---|
| container_issue | 2 |
| container_start_page | 163 |
| container_title | Journal of geriatric oncology |
| container_volume | 9 |
| creator | Honecker, Friedemann Harbeck, Nadia Schnabel, Claudia Wedding, Ulrich Waldenmaier, Dirk Saupe, Steffen Jäger, Elke Schmidt, Marcus Kreienberg, Rolf Müller, Lothar Otremba, Burkhard Dorn, Julia Warm, Mathias Al-Batran, Salah-Eddin de Wit, Maike |
| description | To determine predictive/prognostic factors for patients with metastatic breast cancer (MBC) receiving first-line monochemotherapy using biomarker analysis and geriatric assessment (GA).
Karnofsky Performance Status (KPS) and GA as clinical parameters, and prognostic inflammatory and nutritional index (PINI), and Glasgow prognostic score (GPS) as biomarkers were analyzed for association with clinical outcome within the randomized phase III PEg-LIposomal Doxorubicin vs. CApecitabin iN MBC (PELICAN) trial of first-line pegylated liposomal doxorubicin (PLD) or capecitabine.
Of 210 patients, 38% were >65years old. GA (n=152) classified 74% as fit, 10% as compromised, and 16% as frail. Biomarkers showed no age dependency. In multivariate analysis (n=70) KPS, GA, cumulative illness rating scale-geriatrics (CIRS-G), and GPS were significantly associated with time to progression, and KPS, CIRS-G, and instrumental activities of daily living (IADL) from GA, and PINI showed a significant correlation with overall survival.
GA evaluation was feasible. KPS significantly correlated with efficacy outcomes. Items of a GA and biomarkers of inflammation and nutrition may have prognostic significance in patients with MBC. |
| doi_str_mv | 10.1016/j.jgo.2017.09.009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1954393518</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1879406817301959</els_id><sourcerecordid>1954393518</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-4e2615a0610460bfc56fd64e65ff178a8b493f367ab63abcfd44e142956624083</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhiMEolXpA3BBc-SSYCeOE8MJVaWstAKE4Gw5zrjrJYmDx1tU3oi3xKstPeKLR-Nvftv_XxQvOas44_LNvtrfhqpmvKuYqhhTT4pz3neqFKyTTx9r2Z8Vl0R7lldTK9XJ58VZrVjbylqcF39uMHqTordgiJBoxiWBWUYYfJhN_IGRwC-wmuTzCcEvn3YwYzKUcsvCEDGXYM1iMUJEi_7OL7fgfKRUTn5BmMMSSrvDOaQdRrPev4WvSIcpq7kYZshdiPnKMPvfOMK6M4Sw2Wzgy_V2c_X-E-TnmelF8cyZifDyYb8ovn-4_nb1sdx-vsnUtrRN26RSYC15a5jkTEg2ONtKN0qBsnWOd73pB6Ea18jODLIxg3WjEMhFrVqZDWF9c1G8PumuMfw8ICU9e7I4TWbBcCDNVSsa1bT8iPITamMgiuj0Gn027V5zpo8h6b3OIeljSJopnUPKM68e5A_DjOPjxL9IMvDuBGD-5J3HqMlm6y2OPrub9Bj8f-T_Ar23pOg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1954393518</pqid></control><display><type>article</type><title>Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Honecker, Friedemann ; Harbeck, Nadia ; Schnabel, Claudia ; Wedding, Ulrich ; Waldenmaier, Dirk ; Saupe, Steffen ; Jäger, Elke ; Schmidt, Marcus ; Kreienberg, Rolf ; Müller, Lothar ; Otremba, Burkhard ; Dorn, Julia ; Warm, Mathias ; Al-Batran, Salah-Eddin ; de Wit, Maike</creator><creatorcontrib>Honecker, Friedemann ; Harbeck, Nadia ; Schnabel, Claudia ; Wedding, Ulrich ; Waldenmaier, Dirk ; Saupe, Steffen ; Jäger, Elke ; Schmidt, Marcus ; Kreienberg, Rolf ; Müller, Lothar ; Otremba, Burkhard ; Dorn, Julia ; Warm, Mathias ; Al-Batran, Salah-Eddin ; de Wit, Maike ; on behalf of the PELICAN investigators ; PELICAN investigators</creatorcontrib><description>To determine predictive/prognostic factors for patients with metastatic breast cancer (MBC) receiving first-line monochemotherapy using biomarker analysis and geriatric assessment (GA).
Karnofsky Performance Status (KPS) and GA as clinical parameters, and prognostic inflammatory and nutritional index (PINI), and Glasgow prognostic score (GPS) as biomarkers were analyzed for association with clinical outcome within the randomized phase III PEg-LIposomal Doxorubicin vs. CApecitabin iN MBC (PELICAN) trial of first-line pegylated liposomal doxorubicin (PLD) or capecitabine.
Of 210 patients, 38% were >65years old. GA (n=152) classified 74% as fit, 10% as compromised, and 16% as frail. Biomarkers showed no age dependency. In multivariate analysis (n=70) KPS, GA, cumulative illness rating scale-geriatrics (CIRS-G), and GPS were significantly associated with time to progression, and KPS, CIRS-G, and instrumental activities of daily living (IADL) from GA, and PINI showed a significant correlation with overall survival.
GA evaluation was feasible. KPS significantly correlated with efficacy outcomes. Items of a GA and biomarkers of inflammation and nutrition may have prognostic significance in patients with MBC.</description><identifier>ISSN: 1879-4068</identifier><identifier>EISSN: 1879-4076</identifier><identifier>DOI: 10.1016/j.jgo.2017.09.009</identifier><identifier>PMID: 29055624</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Age Factors ; Aged ; Anthracycline ; Biomarker ; Biomarkers - blood ; Breast Neoplasms - drug therapy ; Capecitabine ; Capecitabine - adverse effects ; Disease Progression ; Doxorubicin - adverse effects ; Doxorubicin - analogs & derivatives ; Elderly ; Female ; Frailty - diagnosis ; Geriatric assessment ; Geriatric Assessment - methods ; Humans ; Karnofsky Performance Status ; Metastatic breast cancer ; Middle Aged ; Pegylated liposomal doxorubicin ; Polyethylene Glycols - adverse effects ; Prognostic factor ; Treatment Outcome</subject><ispartof>Journal of geriatric oncology, 2018-03, Vol.9 (2), p.163-169</ispartof><rights>2017 Elsevier Inc.</rights><rights>Copyright © 2017 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-4e2615a0610460bfc56fd64e65ff178a8b493f367ab63abcfd44e142956624083</citedby><cites>FETCH-LOGICAL-c353t-4e2615a0610460bfc56fd64e65ff178a8b493f367ab63abcfd44e142956624083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jgo.2017.09.009$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29055624$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Honecker, Friedemann</creatorcontrib><creatorcontrib>Harbeck, Nadia</creatorcontrib><creatorcontrib>Schnabel, Claudia</creatorcontrib><creatorcontrib>Wedding, Ulrich</creatorcontrib><creatorcontrib>Waldenmaier, Dirk</creatorcontrib><creatorcontrib>Saupe, Steffen</creatorcontrib><creatorcontrib>Jäger, Elke</creatorcontrib><creatorcontrib>Schmidt, Marcus</creatorcontrib><creatorcontrib>Kreienberg, Rolf</creatorcontrib><creatorcontrib>Müller, Lothar</creatorcontrib><creatorcontrib>Otremba, Burkhard</creatorcontrib><creatorcontrib>Dorn, Julia</creatorcontrib><creatorcontrib>Warm, Mathias</creatorcontrib><creatorcontrib>Al-Batran, Salah-Eddin</creatorcontrib><creatorcontrib>de Wit, Maike</creatorcontrib><creatorcontrib>on behalf of the PELICAN investigators</creatorcontrib><creatorcontrib>PELICAN investigators</creatorcontrib><title>Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial</title><title>Journal of geriatric oncology</title><addtitle>J Geriatr Oncol</addtitle><description>To determine predictive/prognostic factors for patients with metastatic breast cancer (MBC) receiving first-line monochemotherapy using biomarker analysis and geriatric assessment (GA).
Karnofsky Performance Status (KPS) and GA as clinical parameters, and prognostic inflammatory and nutritional index (PINI), and Glasgow prognostic score (GPS) as biomarkers were analyzed for association with clinical outcome within the randomized phase III PEg-LIposomal Doxorubicin vs. CApecitabin iN MBC (PELICAN) trial of first-line pegylated liposomal doxorubicin (PLD) or capecitabine.
Of 210 patients, 38% were >65years old. GA (n=152) classified 74% as fit, 10% as compromised, and 16% as frail. Biomarkers showed no age dependency. In multivariate analysis (n=70) KPS, GA, cumulative illness rating scale-geriatrics (CIRS-G), and GPS were significantly associated with time to progression, and KPS, CIRS-G, and instrumental activities of daily living (IADL) from GA, and PINI showed a significant correlation with overall survival.
GA evaluation was feasible. KPS significantly correlated with efficacy outcomes. Items of a GA and biomarkers of inflammation and nutrition may have prognostic significance in patients with MBC.</description><subject>Age Factors</subject><subject>Aged</subject><subject>Anthracycline</subject><subject>Biomarker</subject><subject>Biomarkers - blood</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Capecitabine</subject><subject>Capecitabine - adverse effects</subject><subject>Disease Progression</subject><subject>Doxorubicin - adverse effects</subject><subject>Doxorubicin - analogs & derivatives</subject><subject>Elderly</subject><subject>Female</subject><subject>Frailty - diagnosis</subject><subject>Geriatric assessment</subject><subject>Geriatric Assessment - methods</subject><subject>Humans</subject><subject>Karnofsky Performance Status</subject><subject>Metastatic breast cancer</subject><subject>Middle Aged</subject><subject>Pegylated liposomal doxorubicin</subject><subject>Polyethylene Glycols - adverse effects</subject><subject>Prognostic factor</subject><subject>Treatment Outcome</subject><issn>1879-4068</issn><issn>1879-4076</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFu1DAQhiMEolXpA3BBc-SSYCeOE8MJVaWstAKE4Gw5zrjrJYmDx1tU3oi3xKstPeKLR-Nvftv_XxQvOas44_LNvtrfhqpmvKuYqhhTT4pz3neqFKyTTx9r2Z8Vl0R7lldTK9XJ58VZrVjbylqcF39uMHqTordgiJBoxiWBWUYYfJhN_IGRwC-wmuTzCcEvn3YwYzKUcsvCEDGXYM1iMUJEi_7OL7fgfKRUTn5BmMMSSrvDOaQdRrPev4WvSIcpq7kYZshdiPnKMPvfOMK6M4Sw2Wzgy_V2c_X-E-TnmelF8cyZifDyYb8ovn-4_nb1sdx-vsnUtrRN26RSYC15a5jkTEg2ONtKN0qBsnWOd73pB6Ea18jODLIxg3WjEMhFrVqZDWF9c1G8PumuMfw8ICU9e7I4TWbBcCDNVSsa1bT8iPITamMgiuj0Gn027V5zpo8h6b3OIeljSJopnUPKM68e5A_DjOPjxL9IMvDuBGD-5J3HqMlm6y2OPrub9Bj8f-T_Ar23pOg</recordid><startdate>201803</startdate><enddate>201803</enddate><creator>Honecker, Friedemann</creator><creator>Harbeck, Nadia</creator><creator>Schnabel, Claudia</creator><creator>Wedding, Ulrich</creator><creator>Waldenmaier, Dirk</creator><creator>Saupe, Steffen</creator><creator>Jäger, Elke</creator><creator>Schmidt, Marcus</creator><creator>Kreienberg, Rolf</creator><creator>Müller, Lothar</creator><creator>Otremba, Burkhard</creator><creator>Dorn, Julia</creator><creator>Warm, Mathias</creator><creator>Al-Batran, Salah-Eddin</creator><creator>de Wit, Maike</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201803</creationdate><title>Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial</title><author>Honecker, Friedemann ; Harbeck, Nadia ; Schnabel, Claudia ; Wedding, Ulrich ; Waldenmaier, Dirk ; Saupe, Steffen ; Jäger, Elke ; Schmidt, Marcus ; Kreienberg, Rolf ; Müller, Lothar ; Otremba, Burkhard ; Dorn, Julia ; Warm, Mathias ; Al-Batran, Salah-Eddin ; de Wit, Maike</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-4e2615a0610460bfc56fd64e65ff178a8b493f367ab63abcfd44e142956624083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Age Factors</topic><topic>Aged</topic><topic>Anthracycline</topic><topic>Biomarker</topic><topic>Biomarkers - blood</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Capecitabine</topic><topic>Capecitabine - adverse effects</topic><topic>Disease Progression</topic><topic>Doxorubicin - adverse effects</topic><topic>Doxorubicin - analogs & derivatives</topic><topic>Elderly</topic><topic>Female</topic><topic>Frailty - diagnosis</topic><topic>Geriatric assessment</topic><topic>Geriatric Assessment - methods</topic><topic>Humans</topic><topic>Karnofsky Performance Status</topic><topic>Metastatic breast cancer</topic><topic>Middle Aged</topic><topic>Pegylated liposomal doxorubicin</topic><topic>Polyethylene Glycols - adverse effects</topic><topic>Prognostic factor</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Honecker, Friedemann</creatorcontrib><creatorcontrib>Harbeck, Nadia</creatorcontrib><creatorcontrib>Schnabel, Claudia</creatorcontrib><creatorcontrib>Wedding, Ulrich</creatorcontrib><creatorcontrib>Waldenmaier, Dirk</creatorcontrib><creatorcontrib>Saupe, Steffen</creatorcontrib><creatorcontrib>Jäger, Elke</creatorcontrib><creatorcontrib>Schmidt, Marcus</creatorcontrib><creatorcontrib>Kreienberg, Rolf</creatorcontrib><creatorcontrib>Müller, Lothar</creatorcontrib><creatorcontrib>Otremba, Burkhard</creatorcontrib><creatorcontrib>Dorn, Julia</creatorcontrib><creatorcontrib>Warm, Mathias</creatorcontrib><creatorcontrib>Al-Batran, Salah-Eddin</creatorcontrib><creatorcontrib>de Wit, Maike</creatorcontrib><creatorcontrib>on behalf of the PELICAN investigators</creatorcontrib><creatorcontrib>PELICAN investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of geriatric oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Honecker, Friedemann</au><au>Harbeck, Nadia</au><au>Schnabel, Claudia</au><au>Wedding, Ulrich</au><au>Waldenmaier, Dirk</au><au>Saupe, Steffen</au><au>Jäger, Elke</au><au>Schmidt, Marcus</au><au>Kreienberg, Rolf</au><au>Müller, Lothar</au><au>Otremba, Burkhard</au><au>Dorn, Julia</au><au>Warm, Mathias</au><au>Al-Batran, Salah-Eddin</au><au>de Wit, Maike</au><aucorp>on behalf of the PELICAN investigators</aucorp><aucorp>PELICAN investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial</atitle><jtitle>Journal of geriatric oncology</jtitle><addtitle>J Geriatr Oncol</addtitle><date>2018-03</date><risdate>2018</risdate><volume>9</volume><issue>2</issue><spage>163</spage><epage>169</epage><pages>163-169</pages><issn>1879-4068</issn><eissn>1879-4076</eissn><abstract>To determine predictive/prognostic factors for patients with metastatic breast cancer (MBC) receiving first-line monochemotherapy using biomarker analysis and geriatric assessment (GA).
Karnofsky Performance Status (KPS) and GA as clinical parameters, and prognostic inflammatory and nutritional index (PINI), and Glasgow prognostic score (GPS) as biomarkers were analyzed for association with clinical outcome within the randomized phase III PEg-LIposomal Doxorubicin vs. CApecitabin iN MBC (PELICAN) trial of first-line pegylated liposomal doxorubicin (PLD) or capecitabine.
Of 210 patients, 38% were >65years old. GA (n=152) classified 74% as fit, 10% as compromised, and 16% as frail. Biomarkers showed no age dependency. In multivariate analysis (n=70) KPS, GA, cumulative illness rating scale-geriatrics (CIRS-G), and GPS were significantly associated with time to progression, and KPS, CIRS-G, and instrumental activities of daily living (IADL) from GA, and PINI showed a significant correlation with overall survival.
GA evaluation was feasible. KPS significantly correlated with efficacy outcomes. Items of a GA and biomarkers of inflammation and nutrition may have prognostic significance in patients with MBC.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>29055624</pmid><doi>10.1016/j.jgo.2017.09.009</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1879-4068 |
| ispartof | Journal of geriatric oncology, 2018-03, Vol.9 (2), p.163-169 |
| issn | 1879-4068 1879-4076 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1954393518 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Age Factors Aged Anthracycline Biomarker Biomarkers - blood Breast Neoplasms - drug therapy Capecitabine Capecitabine - adverse effects Disease Progression Doxorubicin - adverse effects Doxorubicin - analogs & derivatives Elderly Female Frailty - diagnosis Geriatric assessment Geriatric Assessment - methods Humans Karnofsky Performance Status Metastatic breast cancer Middle Aged Pegylated liposomal doxorubicin Polyethylene Glycols - adverse effects Prognostic factor Treatment Outcome |
| title | Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T15%3A07%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Geriatric%20assessment%20and%20biomarkers%20in%20patients%20with%20metastatic%20breast%20cancer%20receiving%20first-line%20mono-chemotherapy:%20Results%20from%20the%20randomized%20phase%20III%20PELICAN%20trial&rft.jtitle=Journal%20of%20geriatric%20oncology&rft.au=Honecker,%20Friedemann&rft.aucorp=on%20behalf%20of%20the%20PELICAN%20investigators&rft.date=2018-03&rft.volume=9&rft.issue=2&rft.spage=163&rft.epage=169&rft.pages=163-169&rft.issn=1879-4068&rft.eissn=1879-4076&rft_id=info:doi/10.1016/j.jgo.2017.09.009&rft_dat=%3Cproquest_cross%3E1954393518%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1954393518&rft_id=info:pmid/29055624&rft_els_id=S1879406817301959&rfr_iscdi=true |